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A B S T R A C T
Purpose
National Cancer Institute of Canada Clinical Trials Group CO.17 demonstrated the antiepidermal
growth factor receptor (anti-EGFR) monoclonal antibody cetuximab improves overall and
progression-free survival in patients with advanced, chemotherapy-refractory colorectal cancer
(CRC), particularly in patients with wild-type KRAS tumors. This article reports the health-related
quality-of-life (HRQL) outcomes from CO.17.
Patients and Methods
Patients (N  572) with pretreated EGFR-detectable advanced CRC were randomly assigned to
cetuximab and best supportive care (BSC) or to BSC alone. HRQL primary end points assessed by
the EORTC QLQ-C30 were physical function (PF) and global health status (GHS); mean changes
from baseline to 8 and 16 weeks were assessed. Post hoc analysis by KRAS mutation status
was performed.
Results
Questionnaire compliance was 94% at baseline, but it declined differentially (67% v 47% for
cetuximab v BSC at 16 weeks). PF change scores were 3.9 for cetuximab and 8.6 for BSC
(P  .046) at 8 weeks and were 5.9 and 12.5 for cetuximab and BSC, respectively, (P  .027)
at 16 weeks. GHS change scores were 0.5 and 7.1 (P  .008) at 8 weeks and were 3.6 and
15.2 (P  .008) at 16 weeks for cetuximab and BSC, respectively. In patients who had tumors
with wild-type KRAS status, cetuximab resulted in less PF deterioration at 8 weeks (0.7 v 7.2;
P  .11) and 16 weeks (3.4 v 13.8; P  .008) compared with BSC. Patients with wild-type
status who received cetuximab experienced improved GHS at 8 weeks, whereas patients who
received BSC alone deteriorated (3.2 v 7.7; P  .002). Cetuximab preserved GHS at 16 weeks
(0.2 v 18.1; P  .001). No significant differences were noted between study arms for patients
with mutated KRAS tumors.
Conclusion
Cetuximab offers important HRQL and survival benefits for pretreated patients with advanced,
wild-type KRAS CRC.
J Clin Oncol 27:1822-1828. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Colorectal cancer (CRC) is the second-most leading
cause of cancer-relateddeath in theWesternworld.1
For patients with advanced CRC, chemotherapy
andthevascular endothelial growth factor–targeting
monoclonal antibody bevacizumab can prolong
survival.2-4 However, except for a minority of pa-
tients with resectable metastases, the disease re-
mains incurable.
Cetuximab, amurinemonoclonal antibodydi-
rected against the epidermal growth factor receptor
(EGFR), has activity inpatientswith advancedCRC.
In 2007, the National Cancer Institute of Canada
Clinical Trials Group (NCIC CTG) and Australa-
sianGastro-IntestinalTrialsGroup(AGITG)CO.17
study demonstrated that, in patients heavily pre-
treated for advanced CRC, treatment with cetux-
imab resulted in prolonged overall survival (OS;
median, 6.1 v 4.6 months; hazard ratio [HR], 0.77;
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P .0046) and progression-free survival (PFS; HR, 0.68; P .001),
improved objective response rate (RR; 8.0 v 0%; P  .0001), and
improved disease control rate (DCR; 31.4 v 10.9%; P  .001) com-
pared with best supportive care (BSC) alone.5
KRAS, aGproteindownstreamofEGFRsignaling,playsapivotal
role in signal transduction after EGFR activation. KRAS mutations
that lead to constitutive activation of the pathway render EGFR inhi-
bition ineffective.6 KRAS mutations, found in approximately 40% of
CRCs, are an important predictor of benefit from EGFR targeting
agents.6-13 InCO.17, benefits of cetuximabweremore pronounced in
patients with wild-type rather than with mutated-KRAS status (OS:
median, 9.5 v4.8months;HR, 0.55;P .001; PFS:HR, 0.40;P .001;
RR: 12.8 v 0%; P .001); P values of interaction between treatment
and KRAS status 0.01 for OS and less than 0.0001 for PFS].13 As
therapeutic benefits appear isolated to patients with wild-type KRAS
tumors across these studies,6-13 it is now accepted that monoclonal
antibody EGFR inhibition should be limited to these patients.
Because the survival for most patients with chemotherapy-
refractoryCRC is short, andbecause of the importance of palliationof
symptoms and minimization of toxicity of therapy, this study in-
cluded prospective evaluation of the effect of cetuximab on health-
related quality of life (HRQL). TheHRQL results of CO.17, including
analyses by KRAS mutation status, are reported here.
PATIENTS AND METHODS
CO.17was a collaborationbetween theNCICCTGand theAGITGconducted
in Canada, Australia, New Zealand, and Singapore. Funding was provided by
theNCICCTG, the AGITG, BristolMyers Squibb, and ImClone Systems Inc.
The NCIC CTGmaintained the trial database and conducted all analyses.
Patients
Included patients had advanced, pretreated, EGFR-detectable, histolog-
ically provenmetastaticCRC forwhichnoother standard anticancer therapies
were available. Patients had Eastern Cooperative Oncology Group perfor-
mance status (PS) scores of 0 to 2. All had prior chemotherapy, including
thymidylate synthase (TS) inhibition (fluorouracil, capecitabine, or ralti-
trexed), and all experienced treatment failure or were considered unsuitable
for treatment with both irinotecan and oxaliplatin. Additional details of the
eligibility criteria have been reported previously.5 Participating centers re-
ceived approval from their institutional ethics review boards. All patients
provided written informed consent before participation.
Study Procedures
Eligible patients were randomly assigned on a 1:1 basis to receive cetuximab
plus BSC or BSC alone. Cetuximab was administered at a standard dosage of
400mg/m2 intravenously (IV)over2hoursondayone followedby250mg/m2
IVweekly.Treatmentwas continueduntil diseaseprogressionorunacceptable
toxicity occurred. BSC was defined as any and all treatments to improve
symptoms and HRQL. The primary study end point was OS. Secondary end
points included PFS, RR, safety, and HRQL. All patients were to complete
HRQL questionnaires.
HRQL Hypothesis
In this heavily pretreated CRC population, in which deterioration in
HRQL may be imminent, we hypothesized a priori that cetuximab therapy
would result in a decrease in the magnitude and rate of decline in HRQL,
particularly in physical functioning and overall well-being.
HRQL Assessment
The European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire C30 (EORTC QLQ-C30), which is a self-
administered, cancer-specific, multidimensional questionnaire, was selected,
because it is valid and reliable in the advanced cancer setting.14 This 30-item
questionnaire includes five functional scales (ie, physical, role, cognitive, emo-
tional, social), a two-item global health status (GHS) scale, three symptom
scales (ie, fatigue, pain,nausea andvomiting), and six single items (ie, dyspnea,
sleep disturbance, appetite loss, constipation, diarrhea, financial impact).15
Scoringwascompletedaccording to theEORTCQLQ-C30manual, and linear
transformation was used to standardize raw scores to range between 0 and
100.16 Higher scores corresponded to better HRQL in functional scales and
GHS and to worse HRQL in symptom scores. Missing items in a scale were
handled by the methods outlined in the scoringmanual.
Thequestionnairewas tobecompleted inclinic atbaselineandat4, 8, 16,
and 24 weeks post–random assignment unless the patient had deteriorated to
a PS of 4 or was hospitalized for end-of-life care.
Statistical Considerations
TheprimaryHRQLanalysesweredefinedprospectively as a comparison
of the change scores frombaseline to 8 and 16weeks, respectively, for physical
function (PF) andGHS scales (Wilcoxon test). These time points were chosen
a priori, as the effects of cetuximab were expected to be evident by 16 weeks.
SecondaryHRQLanalyses, definedprospectively, includedcomparisons
of the proportion of patients withworsened PF andGHS at 8 and 16weeks by
using Fisher’s exact test and the time to deterioration in PF and GHS scales
(defined as time from random assignment to aminimum10-point worsening
in the change score from baseline) by log-rank test.
Exploratory analyses of change scores for all scales and items with the
NCIC CTG basic approach17 categorized all patients for each scale or single
item as having improved (ie, increase of 10 units from baseline at any time
point), having worsened (ie, decrease of 10 units or more without improve-
ment) or having remained stable (ie, change  10 units) in the HRQL re-
sponse. A 10-unit difference in change scores was predefined as clinically
important.18 2 testing was used to compare the distributions of HRQL re-
sponse categories between arms.
HRQL outcomes were analyzed by KRAS status. Paraffin-embedded,
archival tumor samples storedat a central tumorbankatQueen’sUniversity in
Kingston,Canadawereassayed forKRASmutations inablinded fashion in the
Department of Clinical Biomarkers–Oncology at Bristol-Myers Squibb, NJ,
andwere classified asmutated orwild type on the basis of prespecified criteria.
Correlation between HRQL response and objective tumor response was
also sought.
HRQL analyses were based on intention to treat. All randomly assigned
patients with a baseline and at least one other HRQL assessment were assess-
able. The Hochberg method was used to adjust for four comparisons in the
primary analyses.19 To address data missing not at random, two sensitivity
analyses were performed: primary analyses, by using pattern mixture models
withmissing data patterns defined on the basis of lastHRQL assessment and a
linear mixedmodel, which included treatment and a treatment-time interac-
tion term for each pattern;20 and secondary analyses, which assumed that all
patients with missing HRQL data had deteriorated. Differences in demo-
graphics, reported toxicities, andPSofpatientswithorwithoutmissingHRQL
data at 8 and 16 weeks were evaluated.
RESULTS
Patient Characteristics
Five hundred seventy-two patients were randomly assigned; 287
were assigned to the cetuximab arm. Baseline characteristicswerewell
balancedbetween arms.5 Themedian agewas 63 years, and 77%had a
PS of 1 or better. All patients had received a prior TS inhibitor: 96%
received prior irinotecan, and 98% received prior oxaliplatin. Tumor
KRAS mutation status was available retrospectively in 394 patients
(69%). Among them, 164 (42%) had tumors with mutated KRAS.13
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HRQL Compliance
Questionnaire compliance, defined as the number of patients
who completed a questionnaire at a given time point divided by the
number of patients known to be alive but not deteriorated to a PS of 4
and not hospitalized for end-of -life care at that time point, is listed in
Table 1. Compliance was high at baseline ( 90%) but declined over
time, particularly in the BSC arm.
Baseline HRQL Results
The study arms had comparable baseline HRQL scores (Fig 1).
Balanced baseline impairment was seen in the GHSmean scores. The
worst baseline symptom scale was fatigue in both arms.
PF and GHS Change Scores
Patients on BSC alone had a greater magnitude of worsening in
their PF and GHS scores compared with cetuximab, as listed in Table
2. The mean PF change scores for the cetuximab and BSC arms were
3.9 and8.6 (P .046), respectively, at 8weeks andwere5.9 and
12.5 (P .027), respectively, at 16 weeks. The GHS change scores
for the cetuximab and BSC arms were 0.5 and 7.1 (P  .008),
respectively, at 8 weeks and were3.6 and15.2 (P .001), respec-
tively, at 16 weeks. Because all four P values were less than .05, the
Hochberg procedure rejected all four null hypotheses, and the family-
wise probability of a type I error was controlled at .05. Sensitivity
analyses on the basis of pattern mixture models supported conclu-
sions from primary analyses.
In patients with wild-type KRAS tumors, cetuximab resulted in
less deterioration in mean change scores for PF at 8 weeks (0.7 v
7.2;P .11) and16weeks (3.4 v13.8;P .008) comparedwith
BSC alone. The cetuximab patients with wild-type status had a trend
toward improvement inGHSmeanchange score at 8weeks (P .12),
whereas those on the BSC arm had a significant deterioration
(P .009); the difference between groupswas highly significant (3.2 v
7.7; P  .002). GHS mean change score remained superior in the
cetuximab arm at 16 weeks (0.2 v18.1; P .001). These results
were also confirmed in sensitivity analyses that were based on pattern
mixture models. There were no significant differences between study
arms in PF or GHS for patients withmutatedKRAS tumors at 8 or 16
weeks (data not shown).
More patients on BSC had worsened GHS (at least 10 points
decrease) at 8 weeks (38.3 v 23.2%; P  .004) and 16 weeks (49.3 v
31.3%; P  .011), and had a trend toward worsened PF at 8 weeks
(34.7 v 24.9%; P  .051 [Fisher’s exact test]) and 16 weeks (43.4 v
30.4%; P  .069). Among patients on the cetuximab arm, patients
with mutated KRAS status trended toward worsened PF at 8 weeks
(31.3 v 17.8%; P .09) and 16weeks (40.7 v 21.7; P .08) compared
with those who had wild-type KRAS status.
Therewere nodifferences in demographics or reported toxicities
of patients with or without missing HRQL data at 8 and 16 weeks on
either arm. However, patients with missing HRQL data were more
likely tohavePS3 to4ormissing,whereas thosewithHRQLdatawere
more likely to have PS 0 to 2 (data not shown). In a sensitivity analysis
in which all patients withmissing data were considered to have wors-
ened HRQL, 64.3 and 48.3% of patients who received BSC alone or
cetuximab, respectively, had at least a 10-unit deterioration in PF at 8
weeks; 65.8 and 47.2% of patients experienced this at at16 weeks (all
P  .001). The rates of deterioration for GHS with BSC alone or
cetuximabwere 84.0% and 67.7%, respectively, at 8 weeks and 85.9%
and 67.3%, respectively, at 16 weeks (all P .001).
Time to Deterioration in HRQL
Atotalof235patientsoncetuximaband202onBSChadbaseline
and at least onepostbaseline assessment for PF, and233on cetuximab
and 200 on BSC had this for GHS. The median time before clinically
important deterioration in HRQL (ie, at least 10 points decrease), as
measured by the PF,was significantly longer for patients on the cetux-
imabcomparedwith theBSCarm(5.4v3.7months;P .022;Fig2A),
and a trend to significance was measured by GHS (5.4 v 3.7 months;
Table 1. Compliance With Health-Related Quality of Life Assessments
Assessment Time (weeks)
Cetuximab  Best Supportive Care Best Supportive Care Alone
No. Expected
Received
No. Expected
Received
No. % No. %
Baseline 287 269 93.7 285 269 94.4
4 266 230 86.5 270 185 68.5
8 239 194 81.2 238 152 63.9
16 197 132 67.0 172 80 46.5
24 158 96 60.8 113 40 35.4
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Fig 1. Mean health-related quality-of-life scores at baseline. No statistical
differences were seen between arms for any scales or items. (Data for single
items of dyspnea, sleep disturbance, constipation, and diarrhea are not shown).
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P  .062; Fig 2B). Figures 2C to 2D demonstrate that patients on
cetuximab had a longer time to deterioration when patients with
KRASwild-typewere comparedwithmutated status forbothPF(5.7 v
3.4 months; P  .01) and GHS (5.7 v 4.7 months; P  .01). No
differences were seen by KRAS status in the BSC arm.
Change Scores at 8 and 16 Weeks in Other Scales
and Domains
Exploratory comparisonsofmean change scores of all other scale
and single items at 8 and 16weeks found statistically significant differ-
ences between patients in the cetuximab arm and BSC arm, respec-
tively, in the following scales and items at 8 weeks (each favored
cetuximab): role function (5.0 v12.7; P .02), fatigue (1.2 v 8.2;
P .002), nausea (0.7 v 6.2; P .007), pain (0.9 v 8.4; P .001),
dyspnea (0.7 v 7.8; P  .005), sleep (1.6 v 4.3; P  .03), financial
impact (4.5 v 2.0; P .001); and at 16 weeks: role function (7.5 v
23.8; P  .001), social function (3.9 v 11.3; P  .04), fatigue
(2.3 v 15.8; P .001), nausea (0.9 v 11.3; P .001), pain (1.1 v 13.6;
P  .007), dyspnea (1.6 v 23.0; P  .001), appetite (1.8 v 13.3;
P .001), and constipation (0.5 v 11.4;P .02).No other differences
were found.
HRQL Response Analysis
Overall HRQL response during the entire study was assessed
comparing the cetuximab versus the BSC alone arm for each evalua-
tion. All results favored the cetuximab arm, and a statistically signifi-
cantly higher proportion of patients experienced improvements in at
least one time point in pain (47% v 27%; P .001), fatigue (41% v
31%; P .04), nausea (22% v 16%; P .01), dyspnea (22% v 13%;
P .04), and financial impact (23% v 14%; P .003).
Analysis by KRAS status demonstrated that a higher proportion
of patients with wild-type compared to mutated-KRAS status on
cetuximab had improvement in GHS (40 v 19%; P .01) and sleep
(36 v 23%; P  .03). For patients in the BSC arm, KRAS wild-type
status was associated with higher emotional function (P  .01) and
lower financial impact (P .04).
Correlation Between HRQL Response and Objective
Tumor Response
Patients with objective tumor response and disease control were
significantlymore likely to have improvement inHRQL than patients
with progressive disease for the following scales or items: PF, social
functioning, GHS, pain, fatigue, nausea and vomiting, appetite, and
diarrhea, as listed in Table 3.
DISCUSSION
Treatmentwith cetuximab resulted in superiorHRQLcomparedwith
BSCalone. Patientswho received cetuximab experienced significantly
less HRQL deterioration and a longer time before clinically signif-
icant deterioration occurred. These results are important, because—
although cetuximabmonotherapy in heavily pretreated patients with
advanced CRC results in improved OS, PFS, RR, and DCR—the
magnitude of these benefits across the entire study population (ie,
non–KRAS selected) was not large. Although toxicity was considered
manageable, more grades 3 to 4 adverse events were recorded on the
cetuximabarmcomparedwith theBSC-alonearm,5whichneeds tobe
considered in any deliberation regarding use of cetuximab in this
setting. Patient-reported outcomes provide important information in
addition to clinician-graded toxicities.21,22 HRQL results inform pa-
tients’ and clinicians’ treatment choices, particularly in advanced can-
cer settings. Patients and clinicians value HRQL results as part of
informed decision making in oncology.23-26 Thus, our prospective
analysis confirms the palliative benefits of this therapy.
Table 2. Mean Health-Related Quality-of-Life Change Scores for Physical Function and Global Health Status
EORTC QLQ-C30 Scale by Assessment Time
Change Score by Treatment Group
P 
Cetuximab  BSC BSC Alone
No. Mean SD No. Mean SD
Week 8 physical function
Overall 185 3.9 15.6 147 8.6 20.4 .046
KRAS wild-type 90 0.69 13.59 62 7.15 20.26 .11
KRAS mutant 48 6.53 16.30 46 12.9 21.56 .14
Week 8 global health status
Overall 185 0.5 20.4 149 7.1 22.4 .008
KRAS wild-type 88 3.22 19.63 63 7.67 21.34 .0016
KRAS mutant 48 4.69 20.48 47 9.57 24.63 .53
Week 16 physical function
Overall 125 5.9 17.7 76 12.5 21.6 .027
KRAS wild-type 69 3.43 17.93 36 13.8 21.47 .0078
KRAS mutant 27 9.51 19.45 22 9.47 22.85 .72
Week 16 global health status
Overall 128 3.6 22.6 75 15.2 25.8  .001
KRAS wild-type 70 0.24 21.19 36 18.1 27.64  .001
KRAS mutant 28 9.52 19.60 21 13.9 26.79 .62
NOTE. Negative change scores indicate worsening quality of life.
Abbreviations: EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; BSC, best supportive care; SD,
standard deviation.
P value from Wilcoxon test between cetuximab and best supportive care arms.
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This study is the first, to our knowledge, to demonstrate that
selection for cetuximab therapy bywild-typeKRAS status predicts for
meaningful HRQL benefits. Patients with mutated KRAS status did
not achieve HRQL benefits from cetuximab compared with BSC
alone. However, those with wild-typeKRAS status were able tomain-
tain their HRQL with cetuximab. These HRQL findings are support-
ive of the improved survival and increasedRR reported in the patients
with wild-type KRAS status who received cetuximab.
The HRQL benefits seen in this study were statistically and clin-
ically significant. It has been demonstrated previously that a 10%
change in HRQL scores represents a perceptible and meaningful
change to patients.17,18 In keeping with their later trajectory in the
disease course, patients on CO.17 had poorer baseline HRQL scores
comparedwith patients in other studies of advancedCRC. In another
study of patients with CRC and liver metastases, some of whomwere
potential candidates formetastectomy, themean baselineGHS scores
were 71.7 to 79.0 (compared with 60.6 to 62.7 on CO.17), and the
meanbaselinePF scoreswere 78.3 to 87.8 (comparedwith 76.0 to 77.6
on CO.17).27 The baseline scores on CO.17 confirm that this was a
population in whom disease was affecting HRQL and for whom
HRQL benefits might be particularly important.
Missingdata is a challenge inHRQLstudies,17,28,29 particularly in
the advanced-disease setting. This occurred inCO.17, as we sought to
collect HRQL questionnaires beyond disease progression. Question-
naire compliance dropped over time, and a disproportionate level of
missing datawas on the BSC arm. Therewas also a slightly higher rate
ofmissingdata inpatientswithmutatedversuswild-typeKRASon the
cetuximab arm with no differences by KRAS status on the BSC arm
(data not shown). It is clear that there are systematic differences in
compliance between the treatment groups and that HRQL data were
not simply missing at random.
It is important to assess the likely causes of such systematic
differences, the direction, and themagnitude of bias thatmay result.30
Weknow that the patients in theBSC armhadworse PFS andOS. It is
plausible that the patients in the BSC arm were doing more poorly
medically and, thus, were less able to complete questionnaires, as has
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Fig 2. Kaplan-Meier curves for time to deterioration in health-related quality of life for all patients [cetuximab v BSC] on (A) physical function, and (B) global health
status; and for patients on cetuximab by KRAS status on (C) physical function, and (D) global health status.
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been found in other studies.26,31 It may be that the HRQL differences
demonstrated in CO.17 are conservative. The true differencesmay be
of greater magnitude, as the BSC arm may have had a worse HRQL
thanwewere able tomeasure, as supportedbyour sensitivity analyses.
Because cetuximab is associated with a prominent and obvious
rash, blinding was not attempted. This could bias patients’ subjective
HRQL measurements. Bias could result if those on cetuximab were
more likely to report HRQL improvements because they perceived
they were receiving active treatment, resulting in a placebo effect.
Conversely, those on BSCmay have beenmore likely to report wors-
eningHRQL. It is reassuring thatmultiple study end points (OS, PFS,
RR, and across HRQL) all point to improvements with cetuximab.
Our results are additionally strengthened by a priori, clinically driven,
primary and secondaryHRQLhypotheses.32,33 Thebiologic plausibil-
ity of a real HRQL effect is strengthened by the demonstration that
improvements in HRQL were more likely in patients who achieved
disease response. The strongest evidence that these HRQL benefits
were not placebo-related comes from the findings of benefits limited
to thewild-typeKRASpopulation.At the timeof the study,neither the
patients nor the investigators knew the patients’ tumor mutational
statuses or the clinical importance of this factor.
In conclusion, CO.17 has demonstrated that cetuximab offers
clinically important survival and HRQL benefits for pretreated pa-
tients with advanced CRC. These benefits are even greater in magni-
tudewhencetuximabuse is restricted topatientswithwild-typeKRAS
status. Cetuximab should be considered for all suitable patients who
have advanced CRC with wild-type KRAS tumors. Additional re-
search is needed to determine the best timing in the disease course to
offer this treatmentandwhether it shouldbegivenasmonotherapy, in
combination with chemotherapy, or possibly with other biologics.
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Table 3. Health-Related Quality of Life Improvement According to Best Tumor Response
Health-Related Quality-of-Life Domain/Scale
Best Tumor Response
P†
CR  PR (n  19) SD (n  107) PD (n  246)
No. % No. % No. %
Physical 4 21.05 29 27.10 33 13.41  .001
Social 7 36.84 47 43.93 69 28.40 .0097
Global health status 11 57.89 42 39.62 56 22.86 .0013
Pain 10 52.63 57 54.29 73 30.04  .001
Fatigue 12 63.16 51 48.11 72 29.15  .001
Nausea and vomiting 4 21.05 22 20.75 44 17.74 .0178
Appetite loss 8 42.11 41 38.68 54 21.95 .0014
Diarrhea 1 5.26 21 19.81 41 16.60 .0207
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
No. of patients who had a response and at least one change score for the global health status. Numbers for other domains or items may vary by one to three
patients because of missing data.
†P values were calculated with Fisher’s exact test of complete, partial, or stable response v progressive disease.
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